Clinical trials: Metastatic Solid Tumor Cancer
Advanced Solid Tumors
A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)
The study determined the recommended Phase 2 loading and maintenance doses and dose schedules for administering dalotuzumab using dose-limiting toxicities (DLTs) observed during the entire treatment period (Up to 18 months).
- Trial name
- NCT00635778
- Testing
- dalotuzumab
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases, Leptomeningeal Metastasis
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy
This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.
- Trial name
- NCT07199413
- Testing
- SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab
- Sponsor
- Medical College of Wisconsin
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Metastatic Cancer
Metastatic Solid Cancer Clinical Trial
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
- Trial name
- NCT04739618
- Testing
- Keytruda Injectable Product, Yervoy Injectable Product, GM-CSF
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- ImmunSYS, LLC
Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN
- Conditions
- Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
- Trial name
- NCT07187908
- Testing
- Efbemalenograstim alfa Injection
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Henan Cancer Hospital
Melanoma, Non Small Cell Lung Cancer
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression
Exploratory interventional study of prognostic serum biomarkers of cancer progression. Study of the relationship between the blood levels of soluble PDL1 and β2-microglobulin, and the clinical course of a metastatic solid tumor…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Renal Cancer
- Trial name
- Onco-PDL1s/B2M (NCT05426317)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT05327010
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 35 sites in United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
- Conditions
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
- Trial name
- NCT04965818
- Testing
- Futibatinib and Binimetinib
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Taiho Oncology, Inc.
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Radiosurgery Before Surgery for the Treatment of Brain Metastases
This early phase I trial identifies the side effects of stereotactic radiosurgery before surgery in treating patients with cancer that has spread to the brain (brain metastases).
- Trial name
- NCT04895592
- Testing
- Dexamethasone, Resection, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Emory University
Locally Advanced Solid Tumor, Metastatic Tumor
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question[s] it aims to answer are: What is the recommended dose patients can safely receive? How long does this drug remain in the…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- Trial name
- NCT05731271
- Testing
- TST003
- Where
- 3 sites in United States
- Volunteers
- 111 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004243
- Testing
- docetaxel, oxaliplatin
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Solid Tumours
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours
This is a single-centre, single arm, open-label pilot study to evaluate the safety and feasibility of CAR-NK cell treatment in subjects with metastatic solid tumours.
- Trial name
- NCT03415100
- Testing
- CAR-NK cells targeting NKG2D ligands
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Solid Tumors, Adult
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up…
- Trial name
- NCT05430373
- Testing
- GT101
- Where
- 5 sites in China
- Volunteers
- 31 people
- Sponsor
- Grit Biotechnology
Solid Tumor
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Phase 1 (dose escalation) of this study will evaluate: The safety and tolerability of EU103 treatment are evaluated for patients with advanced or metastatic solid tumors who have failed standard therapy to determine the maximum…
- Trial name
- NCT05798026
- Testing
- EU103
- Where
- 3 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Eutilex
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.